RYTM - Rhythm Pharmaceuticals Inc Stock Price, Fair Value and News

49.05USD-0.56 (-1.13%)Market Closed

Market Summary

USD49.05-0.56

Market Closed

-1.13%

RYTM Alerts

1 major insider sales recently.

RYTM Stock Price

View Fullscreen

RYTM RSI Chart

RYTM Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-10.92

Price/Sales (Trailing)

32.53

EV/EBITDA

-11.18

Price/Free Cashflow

-21.29

RYTM Price/Sales (Trailing)

RYTM Profitability

EBT Margin

-302.94%

Return on Equity

-444.73%

Return on Assets

-105.88%

Free Cashflow Yield

-4.7%

RYTM Fundamentals

RYTM Revenue

Revenue (TTM)

91.9M

Rev. Growth (Yr)

126.41%

Rev. Growth (Qtr)

7.15%

RYTM Earnings

Earnings (TTM)

-273.9M

Earnings Growth (Yr)

-170.94%

Earnings Growth (Qtr)

-239.57%

Breaking Down RYTM Revenue

Last 7 days

0.7%

Last 30 days

16.1%

Last 90 days

29.6%

Trailing 12 Months

181.2%

How does RYTM drawdown profile look like?

RYTM Financial Health

Current Ratio

4.35

Debt/Equity

1.18

Debt/Cashflow

-1.93

RYTM Investor Care

Shares Dilution (1Y)

7.24%

Diluted EPS (TTM)

-3.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	91.9M	0	0	0
2023	33.6M	43.8M	62.0M	77.4M
2022	8.3M	13.4M	18.5M	23.6M
2021	0	0	0	3.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and AlstrÃƒÆ’Ã‚Â¶m syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

CEO	Dr. David P. Meeker M.D.
WEBSITE	https://rhythmtx.com
INDUSTRY	Biotechnology
EMPLOYEES	177

Rhythm Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rhythm Pharmaceuticals Inc? What does RYTM stand for in stocks?

RYTM is the stock ticker symbol of Rhythm Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rhythm Pharmaceuticals Inc (RYTM)?

As of Thu Jul 25 2024, market cap of Rhythm Pharmaceuticals Inc is 3.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RYTM stock?

You can check RYTM's fair value in chart for subscribers.

Is Rhythm Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RYTM is over valued or under valued. Whether Rhythm Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rhythm Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RYTM.

What is Rhythm Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, RYTM's PE ratio (Price to Earnings) is -11.04 and Price to Sales (PS) ratio is 32.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RYTM PE ratio will change depending on the future growth rate expectations of investors.